Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 1.00 |
| ▸ | YWHAG | P61981 | 1/20 | 1.00 |
| ▸ | YWHAZ | P63104 | 1/20 | 1.00 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | CDK2 | P24941 | 2/20 | 0.69 |
| ▸ | APEX1 | P27695 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | RGS12 | O14924 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32686684 | 1.00 | P2RX7 (1.00) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL14702229 | 1.00 | P2RX7 (1.00) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL7093516 | 0.91 | P2RX7 (0.83) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL7091297 | 0.91 | P2RX7 (0.83) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL7094321 | 0.88 | P2RX7 (0.79) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL7096142 | 0.88 | P2RX7 (0.78) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL7093732 | 0.88 | P2RX7 (0.78) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL7093360 | 0.86 | P2RX7 (0.75) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL7094651 | 0.85 | P2RX7 (0.74) | P2RX7YWHAGYWHAZP2RY1MAPT | |
| SCHEMBL7090990 | 0.85 | P2RX7 (0.74) | P2RX7YWHAGYWHAZP2RY1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367144-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | REMICINE IP B V (NL) | 2025-12-04 | — | — | US | disclosed |
| US-12419848-B2 | Treatment of hyperinflammatory syndrome | Remicine IP B.V. (NL) | 2025-09-23 | — | — | US | disclosed |
| EP-4582147-A2 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Remicine IP B.V. (NL) | 2025-07-09 | — | — | EP | disclosed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4125843-B1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | REMICINE IP B V (NL) | 2025-05-21 | — | — | EP | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4197533-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Guerin, Patrick (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20230128348-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Remicine IP B.V. (NL) | 2023-04-27 | — | — | US | disclosed |
| EP-4125843-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Nomoreitis B.V. (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115605194-A | Treatment of excessive inflammatory syndrome | 诺莫雷蒂斯私人有限公司（BE） | 2023-01-13 | — | — | CN | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | P2RX7 277/4885YWHAG 4271/4885YWHAZ 4635/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | P2RX7 230/4885YWHAG 3989/4885YWHAZ 4526/4885 |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | P2RX7 277/4885YWHAG 4271/4885YWHAZ 4635/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | P2RX7 277/4885YWHAG 4271/4885YWHAZ 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.